2010
Does Myocardial Perfusion Imaging Provide Incremental Prognostic Information to Left Ventricular Ejection Fraction?
Mudrick DW, Velazquez E, Borges-Neto S. Does Myocardial Perfusion Imaging Provide Incremental Prognostic Information to Left Ventricular Ejection Fraction? Current Cardiology Reports 2010, 12: 155-161. PMID: 20425171, DOI: 10.1007/s11886-010-0093-x.Peer-Reviewed Original ResearchMeSH KeywordsCardiac-Gated Single-Photon Emission Computer-Assisted TomographyCoronary Artery DiseaseDeath, Sudden, CardiacHumansMass ScreeningMyocardial Perfusion ImagingPositron-Emission TomographyPredictive Value of TestsPrognosisRisk AssessmentSensitivity and SpecificityStroke VolumeVentricular Function, LeftConceptsEjection fractionVentricular functionNonfatal cardiac eventsGated single-photon emissionIncremental prognostic informationSignificant coronary diseaseVentricular ejection fractionCoronary artery diseaseOptimal treatment strategySudden cardiac deathNuclear imaging studiesImportant clinical implicationsMyocardial perfusion imagingPositron emission tomographySingle photon emissionIschemic burdenCardiac eventsArtery diseaseCardiac deathCoronary diseasePrognostic informationTreatment strategiesMyocardial perfusionPerfusion imagingBest predictor
2007
A Woman With Chronic Urticaria and Graves Disease
Goldberg P, Mayerson A. A Woman With Chronic Urticaria and Graves Disease. The Endocrinologist 2007, 17: 217-220. DOI: 10.1097/ten.0b013e3181237999.Peer-Reviewed Case Reports and Technical NotesChronic urticariaGraves' diseaseElevated thyroid peroxidase antibodiesNormal thyroid function testsNew-onset hyperthyroidismNear-total thyroidectomyThyroid peroxidase antibodiesDay of surgeryThyroid-stimulating immunoglobulinThyroid function testsAutoimmune thyroid diseaseMU/LSeverity of urticariaElevated thyroxine levelsInitial laboratory evaluationNuclear imaging studiesDiffuse myalgiaStandard therapyThyroid autoimmunityClinical courseMedical therapyPeroxidase antibodiesTherapeutic trialsThyrotropin levelsFunction tests
2003
Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?
Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, O’Connor C. Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? American Heart Journal 2003, 145: 758-767. PMID: 12766731, DOI: 10.1016/s0002-8703(02)94818-0.Peer-Reviewed Original ResearchMeSH KeywordsCoronary DiseaseFemaleFluorodeoxyglucose F18Heart FailureHumansMaleMyocardial RevascularizationProspective StudiesRadiopharmaceuticalsRetrospective StudiesSurvival RateThallium RadioisotopesTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsSignificant coronary artery diseaseCoronary artery diseaseLong-term mortalityArtery diseaseSurvival rateHeart failureTreatment strategiesImpaired left ventricular functionLong-term mortality ratesIschemic heart failureLeft ventricular functionIntermediate survival ratesNuclear imaging studiesLack of randomizationLower survival rateEjection fractionVentricular functionViable myocardiumReferral biasStudy protocolTreatment allocationLarge cohortPrognostic studiesMortality ratePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply